Welcome to our dedicated page for Surgery Partners SEC filings (Ticker: SGRY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Surgery Partners, Inc. (SGRY) SEC filings page provides access to the company’s regulatory disclosures as a Nasdaq-listed healthcare services company focused on short-stay and outpatient surgical care. Through these filings, investors can review detailed information about the business, its capital structure, governance and financial performance.
Surgery Partners’ annual reports on Form 10-K and quarterly reports on Form 10-Q describe its outpatient delivery model, the composition of its network of ambulatory surgery centers, surgical hospitals, multi-specialty physician practices and urgent care facilities, and the risks associated with operating in the healthcare sector. These reports also present audited and interim financial statements, management’s discussion and analysis, and risk factor disclosures related to reimbursement, regulation, physician relationships, supply chain, cybersecurity and indebtedness.
Current reports on Form 8-K highlight material events such as debt issuances, credit agreement amendments, earnings releases and leadership changes. For example, recent 8-K filings describe the issuance of additional 7.250% senior notes due 2032 by subsidiary Surgery Center Holdings, Inc., the execution of a second amendment to the company’s credit agreement establishing refinancing term loans and revolving credit commitments, and the announcement of quarterly financial results. Other 8-Ks report board and executive transitions, including resignations, appointments and related employment agreements.
Filings related to capital markets activity, such as indentures for senior notes and amendments to credit facilities, provide insight into interest rates, maturities, guarantees and covenants that shape Surgery Partners’ financial obligations. These documents are important for understanding leverage, refinancing plans and the structure of obligations at the operating subsidiary level.
On this page, AI-powered tools can help summarize lengthy filings, highlight key terms in debt agreements, and clarify the implications of earnings releases and non-GAAP measures like Adjusted EBITDA. Investors can use these summaries to quickly identify items such as revenue trends, same-facility performance, liquidity metrics, leverage ratios and governance changes, while still having direct access to the full text of Forms 10-K, 10-Q, 8-K and related exhibits filed with the SEC.
Surgery Partners, Inc. reported that Harrison R. Bane, its National Group President, has decided to resign from his current role, effective October 3, 2025. The company states that Mr. Bane’s resignation is not due to any disagreement with Surgery Partners on operations, policies, or practices, indicating this is a personal or career decision rather than a dispute with the company.
Surgery Partners, Inc. (SGRY) Form 144 notice records a proposed sale of 100,000 shares of common stock through UBS Financial Services, scheduled approximately for 09/11/2025. The shares were acquired on 09/11/2025 via equity compensation (equity option exercise) from Surgery Partners, Inc. The filing reports the aggregate market value for the 100,000 shares as $2,201,000 and shows 128,209,410 shares outstanding. The filer also disclosed multiple recent sales by Wayne DeVeydt between 08/21/2025 and 09/08/2025, listing transaction sizes and gross proceeds for each sale. The notice includes the standard representations that the seller is not aware of any undisclosed material adverse information and that intentional misstatements are unlawful.
Surgery Partners, Inc. (SGRY) Form 144: The filing notifies a proposed sale of 2,014 common shares through UBS Financial Services with an aggregate market value of $45,217, to be sold on 09/08/2025. The shares were acquired the same day via equity compensation (equity option exercise) from Surgery Partners, Inc.
The filing also discloses prior sales by Wayne DeVeydt between 08/21/2025 and 09/05/2025 totaling 236,865 common shares for gross proceeds of $5,392,323. The form includes the mandatory representation that the seller is not aware of any undisclosed material adverse information.
Surgery Partners insider sale to cover tax withholding reduced holdings. National Group President Harrison R. Bane reported two stock sale transactions on 09/04/2025 at $22.48 per share, disposing of 5,726 and 3,613 shares respectively to satisfy tax withholding related to restricted stock vesting on 09/01/2025. After the sales, he beneficially owned 117,181 shares. The Form 4 was signed by an attorney-in-fact on 09/08/2025.
Surgery Partners, Inc. (SGRY) Form 144 shows an insider notice for the proposed sale of 25,000 shares of common stock to be executed through UBS Financial Services on 09/05/2025 with an aggregate market value listed at $563,700. The filing states those 25,000 shares were acquired the same day, 09/05/2025, as equity compensation from Surgery Partners, Inc., and the payment/transfer is described as an equity option exercise. The filing also lists multiple recent open-market sales by the same individual, Wayne DeVeydt, during August and early September 2025, including transactions of 100,000; 25,000; 11,865; and several 25,000-share sales with disclosed gross proceeds for each trade. The notice includes the standard insider attestation that no undisclosed material adverse information is known.
Surgery Partners, Inc. (SGRY) Form 144 shows a proposed sale of 25,000 common shares through UBS Financial Services on 09/04/2025 with an aggregate market value of $562,766. The shares were acquired the same day via equity compensation from Surgery Partners and were paid for by an equity option exercise. The filing also discloses that Wayne DeVeydt sold a total of 187,865 common shares in the prior three months for aggregate gross proceeds of $4,265,885 across five transactions dated 08/21/2025 through 09/03/2025. The filer affirms no undisclosed material adverse information.
Surgery Partners, Inc. (SGRY) Form 144: This notice reports a proposed sale of 9,339 shares of common stock to be executed through UBS Financial Services Inc. on or about 09/04/2025 with an aggregate market value of $209,944. The shares were acquired on 09/01/2025 through equity vesting as equity compensation from Surgery Partners, Inc.
The filing lists 128,209,410 shares outstanding for the issuer. Several standard filer and issuer identification fields (including the name of the person for whose account the securities are to be sold and filer CIK/CCC) are not populated in the provided content.
Surgery Partners, Inc. (SGRY) Form 144 notice reports a proposed sale of 25,000 common shares through UBS Financial Services on NASDAQ, with an aggregate market value of $560,250 and approximately 128,209,410 shares outstanding. The filing shows the shares were acquired and exercised as equity compensation on 09/03/2025 and are scheduled for sale the same day via an equity option exercise. The filer also disclosed four recent sales by the same person totaling 161,865 shares with gross proceeds shown for each transaction. The notice includes the filer’s certification that no undisclosed material adverse information is known.
Surgery Partners, Inc. insider sale notice (Form 144) reports that 25,000 shares of common stock will be offered for sale through UBS Financial Services with an aggregate market value of $562,000, representing a small fraction of the company's ~128.2 million shares outstanding. The shares were acquired and the sale was effected on 09/02/2025 through equity option exercise. Recent related transactions by the same person, Wayne DeVeydt, show sales of 100,000, 25,000 and 11,865 shares on 08/21/2025, 08/26/2025 and 08/27/2025, generating gross proceeds of $2,299,011; $572,717; and $271,756 respectively. The filer affirms no undisclosed material adverse information.
Form 144 filed for Surgery Partners, Inc. (SGRY) proposing the sale of 11,865 common shares through UBS Financial Services on 08/27/2025. The shares were acquired on 08/27/2025 as equity compensation via an option exercise from Surgery Partners, Inc. The filing reports the issuer has 128,209,410 shares outstanding and lists the planned sale’s aggregate market value as $271,755. The notice also discloses prior dispositions by the same person in the past three months: 25,000 shares sold on 08/26/2025 for $535,339 and 100,000 shares sold on 08/21/2025 for $2,299,011. The filer represents no undisclosed material adverse information is known.